Drug Trial Radar · NCT01216072
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Feb 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,053
Actual
Start
Aug 2010
Primary completion
Aug 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 7, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fingolimod vs. standard of care DMT.
Conditions
- Relapsing Forms of Multiple Sclerosis
Interventions
FingolimodDrug
0.5 mg/day oral capsule
Standard MS DMTsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6Time frame: Baseline, Month 6
Locations
149 sites in 3 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Cullman, Alabama
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Tucson, Arizona
Novartis Investigative Site
Anaheim, California
Novartis Investigative Site
Berkeley, California
Novartis Investigative Site
Fresno, California
Novartis Investigative Site
Fullerton, California
Novartis Investigative Site
La Habra, California
Novartis Investigative Site
Loma Linda, California
Novartis Investigative Site
Newport Beach, California
Novartis Investigative Site
Oceanside, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Walnut Creek, California
Novartis Investigative Site
Boulder, Colorado
Novartis Investigative Site
Colorado Springs, Colorado
Novartis Investigative Site
Fort Collins, Colorado
Novartis Investigative Site
Fairfield, Connecticut
Novartis Investigative Site
New London, Connecticut
Novartis Investigative Site
Stratford, Connecticut
Novartis Investigative Site
Dover, Delaware
Novartis Investigative Site
Newark, Delaware
Novartis Investigative Site
Atlantis, Florida
Novartis Investigative Site
Bradenton, Florida
Novartis Investigative Site
Doral, Florida
Novartis Investigative Site
Fort Lauderdale, Florida
Novartis Investigative Site
Hollywood, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Jacksonville, Florida
Novartis Investigative Site
Lighthouse PT, Florida
Novartis Investigative Site
Maitland, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Pompano Beach, Florida
Novartis Investigative Site
Ponte Vedra Beach, Florida
Novartis Investigative Site
Port Orange, Florida
Novartis Investigative Site
Sarasota, Florida
Showing 40 of 149 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.